Literature DB >> 8163045

Relationship of skeletal muscle glucose 6-phosphate to glucose disposal rate and glycogen synthase activity in insulin-resistant and non-insulin-dependent diabetic rhesus monkeys.

H K Ortmeyer1, N L Bodkin, B C Hansen.   

Abstract

Reduced insulin action on skeletal muscle glycogen synthase activity and reduced whole-body insulin-mediated glucose disposal rates in insulin-resistant subjects may be associated with an alteration in muscle glucose transport (or phosphorylation) or with a defect distal to glucose 6-phosphate. To examine this issue we determined the glucose 6-phosphate concentration and glycogen synthase activity in muscle samples obtained under basal and euglycaemic hyperinsulinaemic clamp conditions in 27 rhesus monkeys (Macaca mulatta). They ranged from metabolically normal (n = 11) to insulin-resistant (n = 8) to overtly diabetic (non-insulin-dependent) (n = 8). The glucose 6-phosphate measured under insulin-stimulated conditions was inversely correlated to insulin-stimulated glycogen synthase independent activity (r = -0.54, p < 0.005), the change in glycogen synthase independent activity (insulin-stimulated minus basal) (r = -0.58, p < 0.002) and to whole-body insulin-mediated glucose disposal rate (r = -0.60, p < 0.002). The insulin-resistant and diabetic monkeys had significantly higher insulin-stimulated glucose 6-phosphate concentrations (0.57 +/- 0.11 and 0.62 +/- 0.11 nmol/mg dry weight, respectively) compared to the normal monkeys (0.29 +/- 0.05 nmol/mg dry weight) (p's < 0.05). We conclude that under euglycaemic/hyperinsulinaemic conditions, a defect distal to glucose 6-phosphate is a major contributor to reduced whole-body insulin-mediated glucose disposal rates and to reduced insulin action on glycogen synthase in insulin-resistant and diabetic monkeys.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163045     DOI: 10.1007/s001250050082

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  24 in total

1.  Synthesis of muscle glycogen during recovery after prolonged severe exercise in diabetic and non-diabetic subjects.

Authors:  S Maehlum; A T Høstmark; L Hermansen
Journal:  Scand J Clin Lab Invest       Date:  1977-06       Impact factor: 1.713

2.  Impaired activation of glycogen synthase in people at increased risk for developing NIDDM.

Authors:  C Schalin-Jäntti; M Härkonen; L C Groop
Journal:  Diabetes       Date:  1992-05       Impact factor: 9.461

3.  Impaired insulin-stimulated muscle glycogen synthase activation in vivo in man is related to low fasting glycogen synthase phosphatase activity.

Authors:  D Freymond; C Bogardus; M Okubo; K Stone; D Mott
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

4.  Relative contribution of glycogen synthesis and glycolysis to insulin-mediated glucose uptake. A dose-response euglycemic clamp study in normal and diabetic rats.

Authors:  L Rossetti; A Giaccari
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

5.  Hyperglycaemia compensates for the defects in insulin-mediated glucose metabolism and in the activation of glycogen synthase in the skeletal muscle of patients with type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  A Vaag; P Damsbo; O Hother-Nielsen; H Beck-Nielsen
Journal:  Diabetologia       Date:  1992-01       Impact factor: 10.122

6.  Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus.

Authors:  A Vaag; J E Henriksen; H Beck-Nielsen
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

7.  Adipose tissue glycogen synthase activation by in vivo insulin in spontaneously insulin-resistant and type 2 (non-insulin-dependent) diabetic rhesus monkeys.

Authors:  H K Ortmeyer; N L Bodkin; B C Hansen
Journal:  Diabetologia       Date:  1993-03       Impact factor: 10.122

8.  Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  P Damsbo; A Vaag; O Hother-Nielsen; H Beck-Nielsen
Journal:  Diabetologia       Date:  1991-04       Impact factor: 10.122

9.  Hyperglycemia markedly enhances skeletal muscle glycogen synthase activity in diabetic, but not in normal conscious rats.

Authors:  S Farrace; L Rossetti
Journal:  Diabetes       Date:  1992-11       Impact factor: 9.461

10.  Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys.

Authors:  H K Ortmeyer; N L Bodkin; K Lilley; J Larner; B C Hansen
Journal:  Endocrinology       Date:  1993-02       Impact factor: 4.736

View more
  4 in total

1.  Impaired activity and gene expression of hexokinase II in muscle from non-insulin-dependent diabetes mellitus patients.

Authors:  H Vestergaard; C Bjørbaek; T Hansen; F S Larsen; D K Granner; O Pedersen
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

2.  Insulin signaling and insulin sensitizing in muscle and liver of obese monkeys: peroxisome proliferator-activated receptor gamma agonist improves defective activation of atypical protein kinase C.

Authors:  Heidi K Ortmeyer; Mini P Sajan; Atsushi Miura; Yoshinore Kanoh; Jose Rivas; Yongxiang Li; Mary L Standaert; Alice S Ryan; Noni L Bodkin; Robert V Farese; Barbara C Hansen
Journal:  Antioxid Redox Signal       Date:  2010-11-23       Impact factor: 8.401

3.  Excessive glucose production, rather than insulin resistance, accounts for hyperglycaemia in recent-onset streptozotocin-diabetic rats.

Authors:  R Burcelin; M Eddouks; J Maury; J Kande; R Assan; J Girard
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

4.  Skeletal muscle weakness is related to insulin resistance in patients with chronic heart failure.

Authors:  Wolfram Doehner; Guelistan Turhan; Francisco Leyva; Mathias Rauchhaus; Anja Sandek; Ewa A Jankowska; Stephan von Haehling; Stefan D Anker
Journal:  ESC Heart Fail       Date:  2015-04-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.